1例克罗恩病患儿使用生物制剂的药学监护

Pharmaceutical Care for A Pediatric Patient with Crohn's Disease Using Biological Agents

目的分析1例先后使用多种生物制剂治疗的克罗恩病(CD)患儿的诊疗过程,为CD患儿的治疗和药学监护提供借鉴。方法通过梳理患儿的疾病诊疗过程,基于文献调研分析药物治疗方案,寻找切入点进行药学监护与用药指导。结果临床药师基于治疗药物监测监护患儿的阿达木单抗维持剂量、疗效、不良反应,及时建议临床调整生物制剂的维持剂量,使患儿从疗效、安全性和经济性等多方面获益。结论临床药师应做好CD患儿的随访,关注患儿使用生物制剂的用药依从性问题与不良反应。

Objective To analyze the diagnosis and treatment process of a pediatric patient with Crohn's disease(CD)who was treated with multiple biological agents,and to provide a reference for the treatment and pharmaceutical care.Methods The diagnosis and treatment process of the pediatric patient’s disease was analyzed.Drug treatment plans were evaluated through literature research to identify the entry points for pharmaceutical care and medication guidance.Results Clinical pharmacist monitored the pediatric patient's adalimumab maintenance dose,efficacy,and adverse reactions through therapeutic drug monitoring.They recommended clinical adjustments to the maintenance dose of biological agents,so that the pediatric patients could benefit from multiple aspects such as efficacy,safety,and economy.Conclusion Clinical pharmacists should follow up with pediatric patients with CD,and pay attention to medication compliance and adverse reactions in those using biological agents.